Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection

Simple item page
dc.contributor.authorHenrik Salje
dc.contributor.authorMaria Theresa Alera
dc.contributor.authorMary Noreen Chua
dc.contributor.authorTaweewun Hunsawong
dc.contributor.authorDamon W. Ellison
dc.contributor.authorAnon Srikiatkhachorn
dc.contributor.authorRichard G. Jarman
dc.contributor.authorGregory D. Gromowski
dc.contributor.authorIsabel Rodríguez-Barraquer
dc.contributor.authorSimon Cauchemez
dc.contributor.authorDerek A. T. Cummings
dc.contributor.authorLouis Macareo
dc.contributor.authorIn‐Kyu Yoon
dc.contributor.authorStefan Fernandez
dc.contributor.authorAlan L. Rothman
dc.date.accessioned2026-05-08T19:14:26Z
dc.date.issued2021-6-24
dc.identifier.doi10.1038/s41591-021-01392-9
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/14556
dc.publisherNature Medicine
dc.subjectMosquito-borne diseases and control
dc.subjectViral Infections and Vectors
dc.subjectViral Infections and Outbreaks Research
dc.titleEvaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection
dc.typeArticle

Files

Collections

All